<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210423051050N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-11</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the Effect of Subcutaneous Injection of Piroxicam in Patients with Non Specific Shoulder Pain</public_title>
      <acronym></acronym>
      <scientific_title>The Comparison of the Effectiveness of Piroxicam Mesotherapy versus Ultrasound-Guided Corticosteroid Injection in Reducing Pain and Improving Function in Patients with Non Specific Shoulder Pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>58</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55888</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To match patients in the intervention and control groups, patients are randomly assigned to one of two treatment groups. The random allocation method in this study will be the permutation blocks randomization method with 4 samples in each block and a random list of data will be obtained by using Random Allocation software. We will have two lists of 29 patients, including the two intervention and control groups, at random. For concealment, method of random sequencing is given to another person who is unaware of the research process, and the questionnaires are completed by a person unaware of the division of groups, Blinding description: Participant: in this study, we does not have the ability to blind the participant because the participant is aware of receiving each intervention. Clinical care giver: we teach the caregiver how to complete the questionnaire. This person is not aware of receiving patient’s intervention. Researcher: this study does not have the ability to blind the researcher due to performing both interventions by himself and being aware of receiving the kind of intervention in each group. The outcome assessor of the complete questionnaires is given to a person who is not aware of the intervention performed and he/she is asked to determine the level of performance in each person according to the questionnaires. Data analyzer: questionnaire are finally given to a person to review the information. This person does not know any of the steps of the work and the way of classification in which the intervention performed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Non Specific Shoulder Pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Subcutaneous injection (mesotherapy) of 1 ml piroxicam 20 mg/ml with 4 ml lidocaine 2% is applied in tender points of the affected shoulder and around the affected shoulder as a grid pattern where each point was at least 1 cm away from the others. Mesotherapy is performed in 3 sessions at intervals of one week according to the common and sterile protocol along with lifestyle modification and doing appropriate exercises for shoulder pain. The patients have to complete the Visual Analog Scale and Oxford Shoulder Score questionnaires before entering the study and 2,4,8 and 12 weeks after intervention. Intervention 2: Control group: Injection of 1 ml corticosteroid methylprednisolone acetate 40 mg/ml with 4 ml lidocaine 2% is applied locally at the site of the lesion and in the affected shoulder under guide of ultrasonography. Corticosteroid injection is performed in one session according to the common and sterile protocol along with lifestyle modification and doing appropriate exercises for shoulder pain. The patients have to complete the Visual Analog Scale and Oxford Shoulder Score questionnaires before entering the study and 2,4,8 and12 weeks after intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All available data can be shared after making people unidentifiable.

When:
Start access period one year after publishing the results.

To whom:
Everyone can access to this information.

Conditions:
If the information in this study helps to improve the science process.

Where to obtain:
Dr. Mohammad Hossein Jabbedari, 00989389443577 , ja.mohammadh@gmail.com

How to obtain:
After sending the desired message, all authors of the study will be consulted all information will be sent within a maximum of three weeks if permitted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Jabbedari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>6th Alley, Takestan Ave., Shahid Rajaei Blvd.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7185988717</zip>
        <telephone>+98 71 3633 2701</telephone>
        <email>ja.mohammadh@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hossein Jabbedari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>6th Alley, Takestan Ave., Shahid Rajaei Blvd.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7185988717</zip>
        <telephone>+98 71 3633 2701</telephone>
        <email>ja.mohammadh@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years of age
Male or Female gender
Completing and signing the informed consent form
Patients with shoulder pain lasted more than 4 weeks and with a shoulder pain Visual Analog Scale (VAS) score of at least 4 in a recent month
Absence of any disease around the affected shoulder joint</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any pathology found on plain radiograph such as degenerative findings of the shoulder joint
Any clinical signs of effusion, inflammation, redness and warmth of the affected shoulder
Diabetes Mellitus
Uncontrolled Hypertension
Rheumatic and Collagen Vascular Diseases such as Lupus and Gout
Concomitant Radiculopathy (cervical radiculopathy), Myopathy, Nerve injuries and Neuropathies (including CTS)
Stroke
Any serious systemic and local infection
Brucellosis
BMI above 42
History of shoulder joint replacement on the affected side
History of shoulder trauma and fracture and severe deformities of the upper limbs
Bleeding tendency and bleeding disorders and/or use of anticoagulants
Inability to communicate and complete questionnaires (Mental and Psychological problems)
History of allergies and allergic reactions to the used drugs including piroxicam, corticosteroids and lidocaine
History of significant liver, kidney, brain and cardiopulmonary disorders
History of intraarticular or periarticular injections at the affected shoulder joint in the last 3 months
History of shoulder and upper limb physiotherapy (physical therapy) in the last 1 month
Pregnant and Lactating women
Patients with Cancer or Malignancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M25.519</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain in unspecified shoulder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Subcutaneous injection (mesotherapy) of 1 ml piroxicam 20 mg/ml with 4 ml lidocaine 2% is applied in tender points of the affected shoulder and around the affected shoulder as a grid pattern where each point was at least 1 cm away from the others. Mesotherapy is performed in 3 sessions at intervals of one week according to the common and sterile protocol along with lifestyle modification and doing appropriate exercises for shoulder pain. The patients have to complete the Visual Analog Scale and Oxford Shoulder Score questionnaires before entering the study and 2,4,8 and 12 weeks after intervention.</i_keyword>
      <i_keyword>Control group: Injection of 1 ml corticosteroid methylprednisolone acetate 40 mg/ml with 4 ml lidocaine 2% is applied locally at the site of the lesion and in the affected shoulder under guide of ultrasonography. Corticosteroid injection is performed in one session according to the common and sterile protocol along with lifestyle modification and doing appropriate exercises for shoulder pain. The patients have to complete the Visual Analog Scale and Oxford Shoulder Score questionnaires before entering the study and 2,4,8 and12 weeks after intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shoulder pain. Timepoint: Before intervention; two weeks, four weeks, eight weeks and twelve weeks later. Method of measurement: Visual Analogue Scale; Oxford Shoulder Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Function of patient. Timepoint: Before intervention; two weeks, four weeks, eight weeks and twelve weeks later. Method of measurement: Oxford Shoulder Score.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-21</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>6th Alley, Takestan Ave., Shahid Rajaei Blvd. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
